By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity […]
Business Continuity and Resiliency Planning for Biomedical and Research Organizations Read Post »
In November 2018, the Government Accountability Office (GAO) released a report titled “FDA Could Improve Designation Review Consistency; Rare Disease
Key Findings from GAO Report on Orphan Drug Approval Modernization Read Post »
This article was originally published by Nigel S. Clarke in World Patent Information Volume 54, Supplement, September 2018, Pages S4-S10 under
This article was originally published by Hao Zhong, Ging Chan, Yuanjia Hu, Hao Hu and Defang Ouyang in Pharmaceutics 2018, 10(4), 263
A Comprehensive Map of FDA-Approved Pharmaceutical Products Read Post »
This paper was originally published by Maxwell Robert Morgan, Owen Gwilym Roberts, and Aled Morgan Edwards in Wellcome Open Res
This is a guest post from Pepper Hamilton Partners John P. Isacson and N. Nicole Stakleff. John can be contacted
Obviousness-Type Double Patenting Just Became Less of a Problem for Innovators Read Post »
This article was originally published by Arun Kumar, Sandeep Kumar, and Arun Nanda in Adv Pharm Bull. 2018 Aug; 8(3): 355–363 under
A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-Crystals Read Post »
This paper was originally published by Emanuel Almeida Moreira de Oliveira and Karen Luise Lang in Journal of Applied Pharmaceutical Science Vol.
There is no simple way to explain drug prices, particularly in the US market, where drug prices vary considerably more
PBMs, Formularies, and Rebates: What Investors Should Know Read Post »
Get fresh news and insights, drug patent expirations & more…
